The transient combination of the IGF-1R inhibitor with continuous osimertinib eradicated the tumor cells and prevented the regrowth in CDX and PDX models of AXL-low-expressing EGFR-mutated NSCLC. This evidence concerns the gene IGF1R and neoplasm.